A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response.
Rifkin
Robert M
RM
US Oncology Research, Inc, The Woodlands, TX, USA. robert.rifkin@usoncology.com
Greenspan
Andrew
A
Schwerkoske
John F
JF
Mandanas
Romeo A
RA
Stephenson
Joe J
JJ
Kannarkat
George T
GT
Zhan
Feng
F
Boehm
Kristi A
KA
Asmar
Lina
L
Beveridge
Roy
R